Hope Biosciences Stem Cell Therapy Shows Significant Motor Function Improvements in Phase II Parkinson's Disease Trial
核心洞察
Hope Biosciences Research Foundation (搜索) reports positive Phase II trial results for allogeneic adipose-derived mesenchymal stem cell therapy in early to moderate Parkinson's disease (搜索) patients.
The randomized, double-blind study of 60 participants demonstrated statistically significant motor function improvements, with the treatment group achieving a mean change of -9.82 points versus -0.50 in placebo on clinician-rated assessments.
Treatment effects increased progressively over six infusions, with the largest effect size of 0.87 observed at the final infusion, substantially exceeding the minimal clinically important difference threshold.
Hope Biosciences Research Foundation (搜索) (HBRF) announced positive top-line results from a Phase II clinical trial evaluating allogeneic adipose-derived mesenchymal stem cell therapy (HB-adMSCs) for patients with early to moderate Parkinson's disease (搜索). The trial successfully met its primary endpoint, demonstrating statistically significant improvements in motor function compared to placebo in this incurable condition that affects approximately one million Americans and is projected to impact 25 million patients globally by 2050.
Trial Design and Results
The randomized, double-blind, single-center study (NCT04995081) enrolled 60 participants equally divided between treatment and placebo groups. Patients in the treatment arm received six intravenous infusions of 200 million stem cells administered over 32 weeks, with study completion at 52 weeks. Primary endpoints measured clinically significant changes in motor function using both patient-reported Motor Experiences of Daily Living (MDS-UPDRS Part II) and clinician-rated Motor Function (MDS-UPDRS Part III) assessments.
The clinician-rated MDS-UPDRS Part III demonstrated progressive and clinically meaningful treatment effects that increased over successive infusions. Effect sizes grew substantially over time, with Cohen's d values of 0.34 at infusion 4, 0.40 at infusion 5, and 0.87 at the sixth and final infusion. By the final infusion, the treatment group achieved a mean change from baseline of -9.82 points versus -0.50 in the placebo group, representing an adjusted mean difference of -9.32 (95% CI [-15.11, -3.54]; p=0.0023). This improvement substantially exceeded the minimal clinically important difference (MCID) of -3.25 points. Bayesian analyses reinforced these findings, confirming both statistical and clinical relevance.
Treatment Pattern and Safety Profile
"The timing of patient improvements is emerging as a key takeaway," said Donna Chang, President of HBRF. "Early infusions showed small improvements in motor function. By the sixth infusion, however, the treatment group showed the largest cumulative improvement. At end of study, we saw a decline in scores from that high point. Taken together, this means that improvements in motor function are possible through treatment with this cellular therapeutic, and that consistent, repeated treatment may be the most promising path forward for sustained enhancement in motor function for individuals living with Parkinson's Disease (搜索)."
The treatment was safe and tolerable in both groups throughout the study period. This marks HBRF's second clinical trial using allogeneic cellular therapeutics, both of which have completed safely, representing progress toward wider adoption of allogeneic therapies that dramatically expand patient access due to reduced manufacturing costs and the ability to serve individuals whose health conditions prohibit banking their own stem cells.
Protocol Validation and Future Directions
Chang highlighted the validation of protocol design as an important achievement, noting divergent results between clinician ratings and patient-reported MDS-UPDRS Part II outcomes. "The subjective nature of patient reporting is something that must be balanced in trial design through inclusion of more objective data-gathering mechanisms that are vital for evaluating therapeutic benefit," Chang explained. "Taking all the data together, in this trial there is a clear treatment effect. We look forward to close out meetings with FDA, and a hopefully fruitful conversation about how we as a community of researchers can continue to balance patient- and clinician-reported outcomes."
HBRF, a 501(c)(3) nonprofit organization, has successfully completed six FDA-authorized protocols in Parkinson's disease (搜索) to date, including a global-first Intermediate Sized Expanded Access protocol for patients aged 76 years and older. With these encouraging Phase II results, the foundation hopes to advance to a Phase III confirmatory trial that could bring the therapy closer to becoming a meaningful new therapeutic option for patients.
"We have had the privilege of serving a significant number of men and women living with Parkinson's, with extremely diverse disease stories," Chang continued. "For this trial, we are eager not only for results of the detailed analysis currently underway, but also to look across the research suite for trends that may inform treatment pathways for Parkinson's in the future."